Beta · prototype— This site is under construction: rankings, texts and features change every week.

Formation Bio

Active#6 worldwide · AI drug discovery

AI drug discovery

HQUnited States
Last roundSeries D · Jun 2024

Uback rankings

How the AI ranks →
RankingTierRankEditionNext update
AI drug discovery · worldwideTop 13#6Edition 0 (beta) · Sep 202621 Nov 2026
Rank historySep 2026 · #6 AI drug discoveryFirst edition: no movements yet.

Estimated valuation

AI · AI drug discovery ranking (worldwide)
≈ USD 1.5bnUSD 1–2.2bn · Unicorn Medium confidence
Anchor
Last known equity round: Series D · USD 372M · Jun 2024

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

DateRoundAmountTypeInvestorsSource
Jun 2024Series DUSD 372MEquityAndreessen Horowitz, Sanofiprnewswire.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Formation Bio as a PDF, on one of three angles only:

ValuationWhat is Formation Bio worth?
Versus competitorsHow does it compare?
Who should acquire itStrategic buyers, and why
Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Comparable companies in ai drug discovery

Full ai drug discovery ranking →

Investors in Formation Bio: Andreessen Horowitz · Sanofi

Sources. prnewswire.com · techcrunch.com

Last updated: Sep 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.